NCT04699838
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04699838
Title Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Muhammad Furqan
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Illinois Medical Center Chicago Illinois 60612 United States Details
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis Indiana 46202 United States Details
University of Iowa Hospitals and Clinics Iowa City Iowa 52242 United States Details
University of Maryland Baltimore Maryland 21201 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field